Literature DB >> 6140703

Variation in oro-facial tardive dyskinesia during depot antipsychotic drug treatment.

T R Barnes, D H Wiles.   

Abstract

Oro-facial (tardive) dyskinesia, occurring in patients on long-term antipsychotic (dopamine antagonist) medication, can be suppressed temporarily by increasing the drug dose. Lowering the dose can exacerbate the condition. In patients receiving regular fluphenazine decanoate (FPZ) and flupenthixol decanoate (FPT) injections, characteristic profiles of the fluctuations in plasma level concentrations, occurring during the injection interval, have been demonstrated. The possible effects of these relatively predictable plasma level changes on the severity of oro-facial dyskinesia, and parkinsonism, were investigated. Regular assessment of oro-facial dyskinesia throughout the injection interval was carried out in six patients receiving FPZ and two patients receiving FPT. In both groups, changes were observed in the severity of oro-facial dyskinesia consistent with the expected effects of drug level fluctuations. The main implication of this finding is that, in investigations of tardive dyskinesia in patients receiving depot medication, ratings should be carried out at a standard time relative to injections.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6140703     DOI: 10.1007/bf00427579

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

1.  Low neuroleptic serum levels in patients receiving fluphenazine decanoate.

Authors:  L E Tune; I Creese; J T Coyle; G Pearlson; S H Snyder
Journal:  Am J Psychiatry       Date:  1980-01       Impact factor: 18.112

2.  A sensitive and specific radioimmunoassay for cis (Z)-flupenthixol in human serum.

Authors:  A Jørgensen
Journal:  Life Sci       Date:  1978-10-16       Impact factor: 5.037

3.  Tardive dyskinesia and depot fluphenazine.

Authors:  D Wiles
Journal:  Br J Psychiatry       Date:  1979-10       Impact factor: 9.319

4.  Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.

Authors:  D H Wiles; M G Gelder
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

5.  Pharmacotherapeutic trials in tardive dyskinesia.

Authors:  A V Mackay; G P Sheppard
Journal:  Br J Psychiatry       Date:  1979-12       Impact factor: 9.319

6.  Plasma-fluphenazine concentrations after injection of long-acting esters.

Authors:  S H Curry; R Whelpton; P J de Schepper; S Vranckx; A A Schiff
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

Review 7.  Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

Authors:  J M Kane; J M Smith
Journal:  Arch Gen Psychiatry       Date:  1982-04

8.  Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man.

Authors:  S H Curry; R Whelpton; P J de Schepper; S Vranckx; A A Schiff
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

9.  Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in Viscoleo.

Authors:  A Jørgensen
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

10.  Tardive dyskinesia: a 3-year follow-up study.

Authors:  T R Barnes; T Kidger; S M Gore
Journal:  Psychol Med       Date:  1983-02       Impact factor: 7.723

View more
  4 in total

1.  Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate.

Authors:  A Viala; B Ba; A Durand; F Gouezo; N Hou; A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

2.  Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.

Authors:  A Viala; N Hou; B Ba; A Durand; H Dufour; N D'Agostino; C Berda; A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

3.  Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose.

Authors:  M F Egan; T M Hyde; J E Kleinman; R J Wyatt
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

Review 4.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.